An Overview of Lung Cancer in Women and the Impact of Estrogen in Lung Carcinogenesis and Lung Cancer Treatment

Vianey Rodriguez-Lara 1* and Maria Rosa Avila-Costa 2

1 Department of Cell and Tissue Biology, Faculty of Medicine, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, 2 Neuromorphology Laboratory, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico

Lung cancer incidence and mortality have significantly increased in women worldwide. Lung adenocarcinoma is the most common form of lung cancer globally. This type of lung cancer shows differences by sex, including the mutational burden, behavior, clinical characteristics, and response to treatment. The effect of sex on lung cancer patients’ survival is still controversial; however, lung adenocarcinoma is considered a different disease in women and men. Moreover, lung adenocarcinoma is strongly influenced by estrogen and is also different depending on the hormonal status of the patient. Young pre-menopausal women have been explored as an independent group. They presented in more advanced stages at diagnosis, exhibited more aggressive tumors, and showed poor survival compared to men and post-menopausal women, supporting the role of sex hormones in this pathology. Several reports indicate the estrogen’s role in lung carcinogenesis and tumor progression. Thus, there are currently some clinical trials testing the efficacy of antihormonal therapy in lung cancer treatment. This mini review shows the updated data about lung cancer in women, its characteristics, the etiological factors that influence carcinogenesis, and the critical role of estrogen in lung cancer and treatment.

Keywords: lung cancer, women, estrogens, antiestrogen medication, adenocarcinoma

INTRODUCTION

Lung cancer in women (LCW) is a severe health problem globally. Smoking habits remain the main factor for its development; however, a high percentage of women with lung cancer (LC) are non-smokers. Therefore, the studies should focus on identifying the risk factors for LCW besides tobacco smoking. Recently, it has been reported that sex and sex hormones may influence LC behavior, survival, and treatment response.

LCW Epidemiology

LCW has significantly increased worldwide in the last years, while in men gradually has decreased, in women has exceeded the incidence and mortality reported for breast cancer, being the leading cause of cancer death in developed countries such as the United States and some from Europe (1–5). Nowadays, LCW has reached third place in incidence and the second place in mortality worldwide with an estimated of 725,352 cases and 576,060 deaths in 2018 (6, 7).
By 2030, LCW is expected to increase 43% in 52 countries with a median of LC age-standardized mortality rates (ASMRs) rising from 11.2 to 16, which will exceed the ASMRs observed for breast cancer (8). Additionally, the current smoking prevalence in adolescent girls from low and middle-income countries of Africa, South America, and the Middle East is higher than that observed in many high-income countries (9), which will increase LCW incidence and mortality in the following years if smoking is not reduced.

LCW increase, mainly in developed countries, could be explained partially by the high tobacco intake (5–9). However, LC has also increased in non-smokers and young women worldwide. Moreover, only 50% of LCW is associated with tobacco smoke. Recently, Jemal and coworkers reported that the increased LC incidence in young women in the USA is not fully explained by smoking patterns (10). Other factors, in addition to tobacco smoking, are essential to developing LCW.

**Characteristics of LCW**

According to the histological features, two types of LC have been described: small-cell lung cancer and non-small cell lung cancer (NSCLC). Currently, the most common type of LC worldwide is the NSCLC, being 85% of all LC diagnosed. There are three NSCLC subtypes: squamous cell carcinoma, lung adenocarcinoma, and large cell carcinoma. Approximately 40 to 60% of LCW correspond to adenocarcinoma, while squamous cell carcinoma is about 10 to 30% of all LC diagnosed (11–13).

Lung adenocarcinoma is a heterogeneous type of cancer and exhibits a lesser association with smoking habits compared to other LC subtypes. It is estimated that up to 50% of women with lung adenocarcinoma are non-smokers, compared to 10–15% of non-smoking men who develop this type of cancer (14).

Clinical characteristics are different between women and men; the diagnosis age in women is lower, women more often have a non-smoking habit, present less advanced stages at diagnosis, and the outcome and survival are significantly better at all stages (11). Hormonal status is rarely considered in studies; however, when pre-menopausal women have been studied independently, they were more commonly diagnosed in advanced stages, exhibited less differentiated tumors, and showed a higher number of metastases and poor prognosis compared to post-menopausal women and men (15–18). It was recently reported that pre-menopausal women exhibit lower overall survival than men and post-menopausal women, supporting the role of sex hormones in LC progression (19).

It is also noteworthy that women with NSCLC respond differently to treatments, being more responsive to chemotherapy (mainly platinum-based treatment), those with adenocarcinoma histology type (13), and for the therapy-based on tyrosine kinase inhibitors (TKIs), but less sensitive to immunotherapy (20–22).

Some LC mutations are more frequent in women, and some genes are differentially expressed by sex. The cytochrome CYP1A1 is overexpressed in women (23), partially explaining tobacco carcinogens’ highest susceptibility, since CYP1A1 bioactivates these compounds. Women have a reduced DNA repair capacity (23) and increased gastrin-releasing peptide receptor (GRPR) that stimulate cancer cell proliferation. Tobacco-related p53 mutations are also more frequent in women (24, 25). All these data suggest that women are more susceptible to tobacco carcinogens than men.

Moreover, women are more likely to be ERCC1-negative, which could explain the chemotherapy treatment benefit compared to men. The Kristen rat sarcoma virus (KRAS) and epidermal growth factor receptor (EGFR) are often overexpressed in women’s lung adenocarcinoma (25). Mutations in EGFR (exon 18–21) are more frequent in women and are associated with estrogen receptor expression (25–28).

**LCW Etiological Factors**

Tobacco smoking remains an essential factor associated with LCW, being more susceptible and having more risk of developing LC than men even in similar smoking exposure (29). The increased incidence of LCW in developed countries has been associated with the changes in smoking habit; however, LCW has risen in young women (30) and even in non-smokers (31), supporting the importance other factors have in lung carcinogenesis in women.

Secondhand smoke is a relevant risk factor in non-smoker women; 64% of deaths due to LC associated with secondhand smoke correspond to women. The passive smoker is exposed to two sources of carcinogens: the smoke generated by the cigarette combustion and the smoker’s smoke exhales. The benzo-a-pyrene diol epoxide, a primary carcinogen of tobacco, is found in both sources (32).

Wood smoke exposure (WSE) affects women mainly in developing countries, where wood is used for cooking and keeping the home warm. For example, it is estimated that 34.4% of non-smoking patients with LC in Mexico were chronically exposed to wood smoke. WSE is associated with adenocarcinoma subtype and higher EGFR mutation (33). WSE produces an increase in MMP-2 and MMP-9, DNA breaks strand, and adducts (34). Deregulation in pathways such as PI3K/AKT, MEK/ERK, and genes involved in DNA repair, cell cycle, apoptosis, and vesicle transport have also been observed in WSE patients with LC (35).

Among non-smokers women, who develop LC in China and India, cooking oil fumes is an important risk factor for developing LC (36). When cooking, oil is brought to high temperatures and generates fumes that contain lung carcinogens, such as polycyclic aromatic hydrocarbons, which produce DNA-oxidative damage and lipid peroxidation (37).

Ambient air pollution, mainly particulate matter (PM2.5), is also associated with a high risk for LC (38), being that the hydrocarbons and heavy metals in the PM compounds carry carcinogenic potential. PM exposure produces inflammation associated with LC (39). Some reports have found that women exhibit a higher risk to air pollution than men (40–42), probably due to their higher susceptibility to carcinogens, reduced DNA repair capacity, and polymorphisms of xenobiotic-metabolizing genes. Ambient air pollution remains a significant risk factor for developing LC in non-smoking women who live in cities with high air pollution levels (43).

Previous reports indicated that the human papillomavirus (HPV) infection could be associated with LCW, since DNA from
HPV16, 18, 30, 31, 33, and 39 were detected in women LC tissues (44–46); however, recent studies rule out this association, since there is no evidence of DNA from HPV in lung tumors, and no differences were found between the presence of HVP in lung tumors and controls (47–49).

Although secondhand smoke, wood combustion, cooking oil fumes, and air pollution are other risk factors to develop LC, particularly in non-smoking women, this does not fully explain the higher LC incidence because a considerable percentage of women were not exposed to these factors. Therefore, it is necessary to identify other etiological factors associated with LCW since up to 50% of cases exhibit non-smoking association.

**Estrogen Role in Lung Carcinogenesis**

Estrogens (E2), through their receptors (ER), regulate several biologic events in addition to their reproductive function. Nuclear estrogen receptor alpha (ERα) and beta (ERβ) are expressed in lung tissue from women and men, playing a role in lung development and physiology (50). The estrogen pathway has also been related to lung carcinogenesis (15).

**Estrogen Receptors and Aromatase Expression in NSCLC**

ER expression has been detected in tumors from patients and NSCLC cell lines (51) and is overexpressed, mainly in lung adenocarcinoma. The ERβ is the most abundant form of ER in LC; it is overexpressed in 60–80% of tumors from women and men (52), and it is related to mutations in ∼500 genes (53).

ERβ expression is associated with hormonal status. The highest expression was found in tumors from pre-menopausal women; lower expression was observed in post-menopausal women. The minimum expression was observed in men (16), suggesting the critical role of circulating estrogen in ER expression.

The G protein-coupled estrogen receptor (GPER) has also been identified in the cytoplasm of NSCLC tumors from women and men, showing higher expression and activity than normal bronchial epithelium (54). GPER expression was associated with LC IIIA and IV stages, lymphoid node metastases, and poorly differentiated tumors. In *vitro*, estrogen increased cell proliferation, migration, and invasion through GPER (55).

Aromatase enzyme (ARO) has also been detected in NSCLC cell lines and ∼86% of tumors. Through ARO, the tumor produces estrogen and activates the estrogen pathway; consequently, it is stimulated by circulating and locally produced estrogen (56). Metastases sites exhibit higher ARO expression than the primary tumor; thus, local estrogen production might also induce the metastases in LC (57).

**Exogenous Estrogen Exposure and LC Risk**

Exogenous estrogen intake and LC risk have also been investigated; however, the results are still controversial. Several studies have shown that hormonal replacement therapy (HRT) is associated with decreased risk of LC and may have a protective effect on the development of NSCLC in women (58, 59). In contrast, some studies report that HRT increases LC incidence (60, 61). A prospective study involved 36,588 women who use combined HRT estrogen-based plus progesterin showed 50% of increased risk after ten or more years of treatment (60). Moreover, the women’s health initiative studies showed that combined HRT was unrelated to LC incidence. Still, a relation to increased mortality from LC, less differentiated tumors, and distant metastases were observed (62). Poor survival in women who use HRT before cancer diagnosis was found compared to women who never use it (39 vs. 79 months) (63). LC risk decreased after HRT cessation (61).

Regarding contraceptive intake, studies found no association with LC increased incidence (64); however, Iversen and coworkers (65) reported an increased risk among ever users who have smoked. The risk of contraceptive intake once LC is developed has not been investigated.

Another exposure form to exogenous estrogen is through endocrine disruptors such as Bisphenol-A (BPA), promoting the migration and invasion of LC cells (66). It was recently reported in the Chinese population that BPA levels were significantly higher in NSCLC patients than in healthy controls; therefore, BPA exposure may be an important risk factor (67).

Estrogen intake does not appear to increase the LC risk; however, once the disease is established, it may increase mortality, probably due to the carcinogenic mechanisms activated by the estrogen pathway.

**Estrogen Pathway in Lung Carcinogenesis**

Estrogen metabolites generate reactive oxygen species (ROS) that cause DNA oxidative damage and form adducts by associating directly to DNA, causing mutations (52). Moreover, through the genomic pathway, the E2/ER complex promotes NSCLC cell proliferation and cell cycle progression by inducing the estrogen expression-dependent genes, c-myc, cyclin D, and Id proteins genes (68, 69). By the non-genomic pathway, E2 activates several pathways that sustain cell proliferation and stimulate tumor growth, such as AMPc, P38K, MAPK, AKT, and ERK (69, 70).

The EGFR pathway is one of the most important signaling pathways in NSCLC since 89% of patients exhibit EGFR overexpression or mutation (71). In NSCLC, E2 activates the EGFR pathway even in the absence of its ligand, promoting cell proliferation, survival, angiogenesis, cell migration, and metastases (72). ERβ expression has also been associated with EGFR mutations (73).

Additionally, estrogen induces angiogenesis through vascular endothelial growth factor (VEGF-A), the ligand of VEGFR-2 expressed in endothelial cells. VEGFR activation produces endothelial cell proliferation to form new vessels that support tumor growth (68).

In *vitro*, E2 stimulated CXCR4 expression and CXCL12/CXCR4 pathway activation in a time and dose-dependent manner, resulting in cell migration (74). This pathway also supports cell proliferation, survival, apoptosis resistance, and angiogenesis and stimulates migration and metastases to the brain, bone, liver, and lymph nodes, the main metastases sites of NSCLC. CXCR4 activation is also related to chemoresistance, maintenance of stem cell characteristics in tumor cells, and immune-resistance by recruiting regulatory T cells (Tregs) to the tumor microenvironment (75, 76).

Estrogen modulates the immune response by modifying the tumor microenvironment, stimulating pro-inflammatory
FIGURE 1 | Estrogen pathway in lung carcinogenesis and its relevance on therapy. Through non-genomic and genomic pathways, estrogen promotes cell proliferation, tumor growth, angiogenesis, cell migration, immunosuppressive responses, and tumor progression since tumor cells overexpressed ERβ. ARO expression maintains elevated E2 levels. The functional relationship between EGFR/EGF and E2/ER pathways sustain the E2 production through ARO expression and the EGFR activation in EGF absence. Preclinical studies have shown antiestrogen treatment efficacy, and in clinical trials, antiestrogen drugs have improved the clinical benefits of TKI and chemotherapy.

cytokines, recruiting Tregs, and promoting cell migration (77). Estrogen induces VEGF secretion by tumor-associated macrophages (TAMs), which support an immunosuppressive tumor microenvironment. ERα expression in lung adenocarcinoma is also associated with Treg recruitment and immunosuppressive response (78).

Nowadays, we know that the estrogen pathway has an essential role in NSCLC, mainly in lung adenocarcinoma, promoting several cancer hallmarks, including cell proliferation, apoptosis resistance, angiogenesis, tumor cell migration and metastases, and probably immune evasion. However, further studies are necessary to fully understand this hormone's relationship with LC progression (Figure 1).

Estrogen Pathway Relevance as a Target in LC Treatment

The antiestrogen drug’s efficacy has been tested in in-vitro and in-vivo assays in NSCLC. Aromatase inhibitors, such as letrozole, significantly decrease cell proliferation, while exemestane reduces tumor growth, increases cell apoptosis, and inhibits cell migration and invasion in vitro (79). The treatment with the estrogen receptor inhibitor, fulvestrant, decreases the tumor growth, the ERβ expression, and the mesenchymal features induced by E2 also increases the chemotherapy sensitivity and T lymphocytes activity (80).

The use of antiestrogen drugs was retrospectively investigated. A higher survival was reported in women who used this therapy previously to be diagnosed with NSCLC than women who never used antiestrogenic treatment (1.89 years vs. 0.93 years, respectively) (81). Also, in clinical trial phases I and II, tamoxifen increased the cisplatin toxicity, and the response to combined therapy was higher than chemotherapy (82). Combined treatment with docetaxel/fulvestrant produced a higher response and overall survival in advanced NSCLC patients than individual chemotherapy (83).

Additionally, the effect of combined antiestrogen and TKI therapy has been investigated in NSCLC due to the functional
relationship between estrogen and EGFR pathways. In vitro, antiestrogen treatment prevents cell proliferation, stimulates apoptosis, reduces tumor growth, and increases the gefitinib sensitivity (84, 85). A phase I clinical trial tested gefitinib plus fulvestrant efficacy. The results showed improved overall survival in NSCLC patients with a mean of 65.5 weeks in those with higher ERβ tumor expression (86). Also, combined therapy (erlotinib/fulvestrant) has been well-tolerated and demonstrates more clinical benefit than TKI monotherapy (87, 88).

Currently, the effectiveness of antiestrogenic therapy on LC is still being investigated. Approximately ten clinical trials study the effects of antiestrogen therapy alone or combined, mainly with TKI, showing clinical benefits in NSCLC patients. These results will be relevant to propose new treatment schemes in LCW patients (Figure 1).

DISCUSSION

LCW has significantly increased, even in young and non-smoking women worldwide. Thus, it is necessary to explore the risk factors that explain this occurrence in the female population to strengthen prevention strategies.

The estrogen pathway has shown an important role in lung carcinogenesis, tumor progression, response to treatment, and survival. The exogenous estrogen could be an important risk factor in women with LC and those with a high risk of developing this disease due to a high percentage of NSCLC express ER/ARO.

Although some estrogen pathways in lung carcinogenesis have been investigated, further studies are necessary to fully understand its role in this disease and its relationship with different critical pathways blocked in targeted therapy to enhance its clinical benefit and decrease the resistance.

Since NSCLC is a different disease in women than in men, and hormonal status influences the behavior of LC, future studies must include the number of women as possible; also, it is essential to separate women by hormonal status since in very few studies have evaluated this variable and could provide vital information to improve the treatment in young pre-menopausal women, whose frequently are diluted in most studies and shows the worst prognosis.

Finally, it is essential to propose specific therapeutic schemes in LC treatment that consider the differences in LC behavior in women since women and men are treated similarly, independently of sex and hormonal status. Because of the relevance that the estrogen pathway has in LC, and with the high percentage of ER expression in LC patients (60–80%), antiestrogen therapy would be an important option for LC treatment. ER detection in NSCLC could be considered in the future to propose better treatment options for women; however, more research is needed in this area.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

ACKNOWLEDGMENTS

The authors wish to thank the Research Division of the Medical School, UNAM, for the financial support.

REFERENCES

1. Malvezzi M, Carisio G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, et al. European cancer mortality predictions for the year 2017 with focus on lung cancer. Ann Oncol. (2017) 28:1117–23. doi: 10.1093/annonc/mdx033
2. Egleston BL, Meireles SI, Flieder DB, Clapper ML. Population-based trends in lung cancer incidence in women. Semin Oncol. (2009) 36:506–15. doi: 10.1053/j.seminoncol.2009.09.003
3. Henley SJ, Gallaway S, Singh SD, O’Neil ME, Buchanan Lunsford N, Momin B, et al. Lung cancer among women in the United States. J Womens Heal. (2018) 27:1307–6. doi: 10.1089/jwh.2018.7397
4. de Grooth PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. Transl Lung Cancer Res. (2018) 7:220–33. doi: 10.21037/tlcr.2018.05.06
5. Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Heal. (2019) 85:8. doi: 10.5334/aogh.2419
6. Globocan. Global Cancer Burden in 2018. (2018). Available online at: http://gco.iarc.fr
7. Siegel RL, Miller KD, Jemal A. Cancer statistics 2020. CA Cancer J Clin. (2020) 70:7–30. doi: 10.3322/caac.21590
8. Martin-Sanchez JC, Lunet N, Gonzalez-Marron A, Lidon-Moyano C, Matilla-Santander N, Cleries R, et al. Projections in breast and lung cancer mortality among women: a bayesian analysis of 52 countries worldwide. Cancer Res. (2018) 78:4436–2. doi: 10.1158/0008-5472.CAN-18-0187
9. Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global cancer in women: burden and trends. Cancer Epidemiol Biomarkers Prev. (2017) 26:444–57. doi: 10.1158/1055-9965.EPI-16-0858
10. Jemal A, Miller KD, Ma J, Siegel RL, Fedewa SA, Islami F, et al. Higher lung cancer incidence in young women than young men in the United States. N Engl J Med. (2018) 378:1999–2009. doi: 10.1056/NEJMoa1715907
11. Radikewicz C, Dickman PW, Johansson ALV, Wagenius G, Edgren G, Lambe M. Sex and survival in non-small cell lung cancer: a nationwide cohort study. PLoS ONE. (2019) 14:e0219206. doi: 10.1371/journal.pone.0219206
12. North CM, Christiani DC. Women and lung cancer: what is new? Semin Thorac Cardiovasc Surg. (2013) 25:87–94. doi: 10.1053/j.semtcv.2013.05.002
13. Barrera-Rodriguez R, Morales-Fuentes J. Lung cancer in women. Lung Cancer. (2012) 73:7–89. doi: 10.2147/LCTT.S37319
14. Nagy-Mignotte H, Guillem P, Vesin A, Toffart AG, Colonna M, Bonetterre V, et al. Primary lung adenocarcinoma: characteristics by smoking habit and sex. Eur Respir J. (2011) 38:1412–9. doi: 10.1183/09031936.00191710
15. Rodriguez-Lara V, Hernandez-Martinez JM, Arrieta O. Influence of estrogen in non-small cell lung cancer and its clinical implications. J Thorac Dis. (2018) 10:482–97. doi: 10.21037/jtd.2017.12.61
16. Rodriguez-Lara V, Pena-Mirabal E, Baez-Saldana R, Esparza-Silva AL, Garcia-Zepeda E, Cervantes Matilla MA, et al. Estrogen receptor beta and CXCR4/CXCL12 expression: differences by sex and hormonal status in lung adenocarcinoma. Arch Med Res. (2014) 45:158–69. doi: 10.1016/j.arcmed.2014.01.001
17. Stabile LP, Dacic S, Land SR, Lenzner DE, Dhir R, Acquafondata M, et al. Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin Cancer Res. (2011) 17:154–64. doi: 10.1158/1078-0432.CCR-10-0992
18. Albain KS, Unger JM, Gotay CC, Davies M, Edelman M, Herbst RS, et al. Toxicity and survival by sex in patients with advance non-small cell lung carcinoma on modern Southwest Oncology Group (SWOG) trials. J Clin Oncol. (2007) 25:7549. doi: 10.1200/jco.2007.25.18_suppl.7549
19. Rodríguez-Lara V, Ramirez-Tirado LA, Barron F, Zatarain-Baron ZL, Flores-Estrada D, Arrieta O. Characteristics of non-small cell lung cancer: differences by sex and hormonal status in a Mexican population. Publica Salud Mex. (2019) 61:265–75. doi: 10.21149/10094
20. Pinto JA, Vallesjos CS, Raez LE, Mas LA, Ruiz R, Torres-Roman JS, et al. Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy? ESMO Open. (2018) 3:e000344. doi: 10.1136/esmoopen-2018-000344
21. Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, et al. Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis. Lancet Oncol. (2018) 19, 737–46. doi: 10.1016/S1470-2241(18)30261-4
22. Wang S, Cowley LA, Liu XS. Sex differences in cancer immunotherapy efficacy, biomarkers, and therapeutic strategy. Molecules. (2019) 24:3214. doi: 10.3390/molecules24183214
23. Kirsch-Volders M, Benassi S, Herceg Z, Hirvonen A, Moller L, Phillips DH. Gender-related differences in response to mutagens and carcinogens. Mutagenesis. (2010) 25:213–21. doi: 10.1039/mutation0905
24. Kligerman S, White C. Epidemiology of lung cancer in women: risk factors, survival, and screening. Am J Roentgenol. (2011) 196:287–95. doi: 10.2221/ArJ.1045.12
25. Planchard D, Loriot Y, Goubar A, Commo F, Soria JC. Differential
26. Li JY, Liu Y, Deng AP. Analysis of the EGFR gene mutation in patients with
27. Ding X, Li L, Tang C, Meng C, Xu W, Wei X, et al. Cytoplasmic
28. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology,
29. Delgado J, Martinez LM, Sanchez TT, Ramirez A, Iturria C, Gonzalez-Avila
30. Ortega-Gomez A, Rangel-Escareno C, Molina-Romero C, Macedo-G, et al. Impact of cooking oil fume exposure and fume extractor use on
31. Liang D, Wang J, Li D, Shi J, Jing J, Shan B, et al. Lung cancer in never-
32. Chen TY, Fang YH, Chen HL, Chang CH, Huang H, Chen YS, et
33. Delgado J, Martinez LM, Sanchez TT, Ramirez A, Iturria C, Gonzalez-Avila
34. Argyri E, Tsimplaki E, Marketos C, Politis G, Panotopoulou E. Investigating
35. He F, Xiong W, Yu F, Xiao R, Ye H, Li W, et al. Human papillomavirus
36. Srinivasan M, Taioli E, Ragin CC. Human papillomavirus type 16 and 18 in primary lung cancers—a meta-analysis. Cancer Res. (2009) 30:1722–8. doi: 10.1039/carcin/bgp177
37. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. (2009) 361:958–67. doi: 10.1056/NEJMo0904554
38. Ding X, Li L, Tang C, Meng C, Xu W, Wei X, et al. Cytoplasmic expression of estrogen receptor β may predict poor outcome of EGFR-TKI therapy in metastatic lung adenocarcinoma. Oncol Lett. (2018) 16:2382–90. doi: 10.3892/ol.2018.8936
39. Engeland A. Trends in the incidence of smoking-associated cancers in Norway, 1954–1993. Int J Cancer. (1996) 68:39–46. doi: 10.1002/(SICI)1097-0215(19960907)68:1<39::AID-IJC>3.0.CO;2-Y
40. Fidler-Benaoudia MM, Torre LA, Bray F, Ferlay J, Jemal A. Lung cancer incidence in young women vs. young men: a systematic analysis in 40 countries. Int J Cancer. (2020) 147:811–9. doi: 10.1002/ijc.32809
41. Li W, Wu M, Zhou Q, Tan L, Zhang J, Wu X, et al. Prognostic relevance of estrogen receptor α, β and γ expression in human nonsmall cell lung cancers using cells procured by laser-capture microdissection. Adv Exp Med Biol. (2008) 617:377–84. doi: 10.1007/978-0-387-69080-3_36
42. Argyri E, Tsimplaki E, Marketos C, Politis G, Panotopoulou E. Investigating the role of human papillomavirus in lung cancer. Papillomavirus Res. (2017) 3–10. doi: 10.1016/j.pvr.2016.12.002
43. He F, Xiong W, Yu F, Xiao R, Ye H, Li W, et al. Human papillomavirus infection maybe not associated with primary lung cancer in the Fujian population of China. Thorac Cancer. (2020) 11:361–9. doi: 10.1111/1759-7714.13282
44. de Freitas AC, Gurgel AP, de Lima EG, de Franca Sao Marcos B, do Amaral CM. Human papillomavirus and lung carcinogenesis: an overview. J Cancer Res Clin Oncol. (2016) 142:2415–27. doi: 10.1007/s00432-016-2197-1
45. Srinivasan M, Taioli E, Ragin CC. Human papillomavirus type 16 and 18 in primary lung cancers—a meta-analysis. Cancer Epidemiol. (2009) 33:1722–8. doi: 10.1039/carcin/bgp177
46. Wang Y, Wang A, Jiang R, Pan H, Huang B, Lu Y, et al. Human papillomavirus type 16 and 18 infection is associated with lung cancer patients from the central part of China. Oncol Rep. (2008) 20:333–9. doi: 10.3892/or_0000011
47. Silva EM, Mariano VS, Pastrez PRA, Pinto MC, Nunes EM, Sichero L, et al. Human papillomavirus is not associated to non-small cell lung cancer: data from a prospective cross-sectional study. Infect Agent Cancer. (2019) 14:18. doi: 10.3892/ia00319-023-0035
48. Argyri E, Tsimplaki E, Marketos C, Politis G, Panotopoulou E. Investigating the role of human papillomavirus in lung cancer. Papillomavirus Res. (2017) 3–10. doi: 10.1016/j.pvr.2016.12.002
49. He F, Xiong W, Yu F, Xiao R, Ye H, Li W, et al. Human papillomavirus infection maybe not associated with primary lung cancer in the Fujian population of China. Thorac Cancer. (2020) 11:361–9. doi: 10.1111/1759-7714.13282
50. Tam A, Morrish D, Wadsworth D, Dorscheid D, Man SF, Sin DD. The role of female hormones on lung function in chronic lung diseases. BMC Womens Health. (2011) 11:24. doi: 10.1186/1472-6874-11-24
51. Kollerup S, Jorgensen K, Bang G, Hauguen A. Expression of estrogen receptors alpha, beta and gamma in lung tissue and cell lines. Lung Cancer. (2002) 37:153–9. doi: 10.1016/S0169-5002(02)00039-9
52. Hershberger PA, Stable IP, Kanterewicz B, Rothstein ME, Gubish CT, Land S, et al. Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells. J Steroid Biochem Mol Biol. (2009) 116:102–9. doi: 10.1016/j.jsbmb.2009.05.004
53. Kerr 2nd A, Elaision JE, Wittliff JL. Steroid receptor and growth factor receptor expression in human nonsmall cell lung cancers using cells procured by laser-capture microdissection. Adv Exp Med Biol. (2008) 617:377–84. doi: 10.1007/978-0-387-69080-3_36
54. Jala VR, Radde BN, Haribabu B, Klinge CM. Enhanced expression of G-protein coupled estrogen receptor (GPER/GPR30) in lung cancer. BMC Cancer. (2012) 12:624. doi: 10.1186/1471-2407-12-624
55. Liu C, Fan S, Tang H, Jiang Z, Zhou B, Xiong J, Zhou S, et al. G protein-coupled estrogen receptor (GPER) mediates NSCLC progression induced by 17β-estradiol (E2) and selective agonist G1. J Med Oncol. (2015) 32:1–13. doi: 10.21320/015-0585-2
56. Skirfalz K, Grindstad T, Khandekhari MR, Richardsen E, Donnem T, Kliyaer T, et al. Prognostic relevance of estrogen receptor alpha, beta and aromatase expression in non-small cell lung cancer. Steroids. (2016) 113:5–13. doi: 10.1016/j.steroids.2016.05.008
57. Niikawa H, Suzuki T, Miki Y, Suzuki S, Nagasaki S, Akahira J, et al. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res. (2008) 14:4417–26. doi: 10.1158/1078-0432.CCR-07-1950

58. Li W, Lin X, Wang R, Wang F, Xie S, Tse LA. Hormone therapy and lung cancer mortality in women: systematic review and meta-analysis. Steroids. (2017) 118:47–54. doi: 10.1016/j.steroids.2016.12.005

59. Titian AL, He H, Lui N, Liou D, Berry M, Shrager JB, et al. The influence of hormone replacement therapy on lung cancer incidence and mortality. J Thorac Cardiovasc Surg. (2020) 159:1546–56.e4. doi: 10.1016/j.jtcvs.2019.10.070

60. Statore CG, Chien JW, Au DH, Satia JA, White E. Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. J Clin Oncol. (2010) 28:1540–6. doi: 10.1200/JCO.2009.25.9739

61. Chlebowski RT, Wakelee H, Pettinger M, Rohan T, Liu J, Simon M, et al. Estrogen plus progestin and lung cancer: follow-up of the women's health initiative randomized trial. Clin Lung Cancer. (2016) 17:10–7.e1. doi: 10.1016/j.cllc.2015.09.004

62. Chlebowski RT, Schwartz AG, Wakelee H, Anderson GL, Stefanick M, et al. Estrogen plus progestin and lung cancer: correlation between epidermal growth factor receptor and estrogen receptor expression in a randomized controlled trial. J Clin Oncol. (2006) 24:59–63. doi: 10.1200/JCO.2005.02.9827

63. Wu W, Yin ZH, Guan P, Ren YW, Zhou BS. Association of oral contraceptives use and lung cancer risk among women: an updated meta-analysis based on cohort and case-control studies. Asian Pac J Cancer Prev. (2014) 15:1205–10. doi: 10.7314/APJCP.2014.15.12.1205

64. Marquez-Garban DC, Mah V, Alavi M, Maresh EL, Chen HW, Bagryanova L, et al. Progesterone and estrogen receptor signaling in non-small cell lung cancer. Endocr Res. (2017) 42:219–31. doi: 10.3978/j.issn.2218-6751.2015.01.01

65. Bellone G, Benthune D, Ridgway N, Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis. (2010) 2:48–51.

66. Deng E, Li M, Shan WL, Qian LT, Meng SP, Zhang XL, et al. Correlation between epidermal growth factor receptor mutations and the expression of estrogen receptor-beta in advanced non-small cell lung cancer. Oncol Lett. (2017) 13:2359–65. doi: 10.3892/ol.2017.7371

67. Rodriguez-Lara V, Ignacio GS, Cerbon Cervantes MA. Estrogen induces CXXCR4 overexpression and CXXCR4/CXL12 pathway activation in lung adenocarcinoma cells in vitro. Endocr Res. (2017) 42:219–31. doi: 10.1074/753800.2017.1292526

68. Xie S, Tu Z, Xiong J, Kang G, Zhao L, Hu W, et al. CXXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner. Oncol Rep. (2017) 37:921–8. doi: 10.3892/or.2016.5269

69. Li Z, Wang Y, Shen Y, Qian C, Oupicky D, Sun M. Targeting pulmonary tumor microenvironment with CXXCR4-inhibiting nanocomplex to enhance anti-PD-L1 immunotherapy. Sci Adv. (2020) 6:eaaz9240. doi: 10.1126/sciadv.aaa9240

70. Rothenberger NJ, Somasundaram A, Stabile LP. The role of the estrogen pathway in the tumor microenvironment. Int J Mol Sci. (2018) 19:611. doi: 10.3390/ijms19020611

71. Navarro FC, Herrreiter C, Nowak L, Stephanie K, Watkins CH. Estrogen regulation of T-cell function and its impact on the tumor microenvironment. Gend Genome. (2018) 2:81–91. doi: 10.17772/470289713880379

72. Giannopoulou E, Satis KE, Metsiou D, Kritikou I, Papachristou DJ, Kalofonou M, et al. The inhibition of aromatase alters the mechanical and rheological properties of non-small cell lung cancer cell lines affecting cell migration. Bioclin Pharmac Biophys. (2015) 1853:328–7. doi: 10.1016/j.bjmac.2014.11.016

73. Hamilton DH, Grinner LM, Keller JM, Hu X, Southall N, Marugan J, et al. Targeting estrogen receptor signaling with fulvestrant enhances immune and chemotherapy-mediated cytotoxicity of human lung cancer. Clin Cancer Res. (2016) 22:6204–16. doi: 10.1158/1078-0432.CCR-15-3059

74. Lother SA, Harding GA, Musto G, Navaratnam S, Pitz MW. Antiestrogen use and survival of women with non-small-cell lung cancer in Manitoba, Canada. Horm Cancer. (2013) 4:270–6. doi: 10.1016/j.sleh.2013.09.039

75. Perez EA, Gandara DR, Edelman MJ, O’Donnell R, Lauder II, DeGregorio M. Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies. Cancer Invest. (2003) 21:1–6. doi: 10.1081/CNV-12003697

76. Sen S, Fu X, Li G, He L, Zhao C, Hu X, et al. Efficacy of tamoxifen in combination with docetaxel in patients with advanced non-small-cell lung cancer pretreated with platinum-based chemotherapy. Anticancer Drugs. (2016) 27:477–56. doi: 10.1097/CAD.0000000000000350

77. Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res. (2005) 65:1459–70. doi: 10.1158/0008-5472.CAN-04-1872

78. Xu R, Sheng H, Guo R, Sun J, Gao W, Shu Y. Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib. Bioclin Pharmacother. (2012) 66:384–9. doi: 10.1016/j.biopharma.2012.02.004

79. Traylor AM, Schiller JH, Stabile LP, Kolesar JM, Eickhoff JC, Dacis S, et al. Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer. (2009) 64:51–9. doi: 10.1016/j.lungcan.2008.07.002

80. Garon EB, Pietras RJ, Finn RS, Karampour N, Pitts S, Marquez-Garban DC, et al. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitor humans in non-small-cell lung cancer. J Thorac Oncol. (2013) 8:270–8. doi: 10.1097/TO.0b013e3182d7525c

81. Garon EB, Siegfried JM, Stabile LP, Young PA, Marquez-Garban DC, Park DJ, et al. Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small-cell lung cancer. Lung Cancer. (2018) 123:91–8. doi: 10.1016/j.lungcan.2018.06.013

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Rodríguez-Lara and Avila-Costa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.